Maxim Group initiated coverage on shares of GW Pharmaceuticals PLC- (NASDAQ:GWPH) in a report issued on Thursday, April 20th. The brokerage issued a buy rating and a $135.00 price objective on the biopharmaceutical company’s stock.
“Epilepsy remains a challenging indication to treat, with over a third of patients (750k patients in the U.S.) who are inadequately controlled despite several antiepileptic drugs (market of $5B) taken concurrently. GW’s lead product, Epidiolex, an orphan drug designated oral CBD (cannabidiol), showed positive results in three P3 trials for Dravet (DS) and Lennox-Gastaut syndromes (LGS).”,” Maxim Group’s analyst commented.
GWPH has been the subject of a number of other reports. Goldman Sachs Group Inc initiated coverage on GW Pharmaceuticals PLC- in a research report on Friday, January 13th. They set a buy rating and a $189.00 price objective for the company. TheStreet raised GW Pharmaceuticals PLC- from a d+ rating to